<prompt> Efalizumab disrupts the interaction between which of the following adhesion molecules?LFA-3 and ICAM-1LFA-1 and ICAM-1LFA-3 and ICAM-3LFA-3 and CD2  <response>: Agents targeting co-stimulatory molecules and under development for psoriasis include: Efalizumab, -A gainst CD11a LFA-1, which blocks CD11a-ICAM-1 binding and may inhibit lymphocyte binding to endothelium the same mechanism. Alefacept - Inhibiting the normal CD2LFA-3 interaction. 